Article
Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.
Drugs - 1 Oct 2024
Maas Dominique P M S M, Willems Loes H, Kranendonk Josephine, Kramers Cornelis, Warlé Michiel C
Abstract excerpt
BACKGROUND: Clopidogrel is widely used for the secondary prevention of atherothrombotic events in patients with coronary artery disease (CAD), ischemic stroke, and peripheral arterial disease (PAD). CYP2C19 plays a pivotal role in the conversion of clopidogrel to its active metabolite. Clopidogrel-treated carriers of a CYP2C19 loss-of-function allele (LOF) may have a higher risk of new atherothrombotic events....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.